Albert Hagelgans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Albert Hagelgans has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Mario Menschikowski
Institute of Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstr. 74, 01307 Dresden, Germany
4 shared publications - Maria Zamaraeva
Laboratory of Molecular Biophysics, Department of Microbiology and Biotechnology, Faculty of Biology, University of Bialystok, 15-245 Bialystok, Poland
3 shared publications - Andrey Yurevich Abramov
Orel State University Russia
2 shared publications - Gabriele Siegert
Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
2 shared publications - Graeme Eisenhofer
University Hospital Carl Gustav Carus, Technische Universität Dresden
2 shared publications Abhishek K. Mishra
Aurobindo Pharma, 2929 Weck Drive, Durham, USA, NC- 27703, USA
1 shared publication
Latest Publications
- 7 August 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 24 (9) , 728-750
Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior
Background: Epigenetic regulation of gene signalling is one of the fundamental molecu-lar mechanisms for the generation and maintenance of cellular memory. Histone acetylation is a common epigenetic mechanism associated with increased gene transcription in the central nervous system (CNS). Stimulation of gene transcription by histone acetylation is important for the devel-opment of CNS-based long-term memory. Histone acetylation is a target for cognitive enhancement via the application of histone deacetylase (HDAC) inhibitors. The promising potential of HDAC in-hibitors has been observed in the treatment of several neurodevelopmental and neurodegenerative diseases. Objective: This study assessed the current state of HDAC inhibition as an approach to cognitive en-hancement and treatment of neurodegenerative diseases. Our analysis provides insights into the mechanism of action of HDAC inhibitors, associated epigenetic priming, and describes the thera-peutic success and potential complications after unsupervised use of the inhibitors. Results and Conclusion: Several chromatin-modifying enzymes play key roles in the regulation of cognitive processes. The importance of HDAC signaling in the brain is highlighted in this review. Recent advancements in the field of cognitive epigenetics are supported by the successful develop-ment of various HDAC inhibitors, demonstrating effective treatment of mood-associated disorders. The current review discusses the therapeutic potential of HDAC inhibition and observed complica-tions after mood and cognitive enhancement therapies.
- 7 August 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 24 (9) , 728-750
Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior
Background: Epigenetic regulation of gene signalling is one of the fundamental molecu-lar mechanisms for the generation and maintenance of cellular memory. Histone acetylation is a common epigenetic mechanism associated with increased gene transcription in the central nervous system (CNS). Stimulation of gene transcription by histone acetylation is important for the devel-opment of CNS-based long-term memory. Histone acetylation is a target for cognitive enhancement via the application of histone deacetylase (HDAC) inhibitors. The promising potential of HDAC in-hibitors has been observed in the treatment of several neurodevelopmental and neurodegenerative diseases. Objective: This study assessed the current state of HDAC inhibition as an approach to cognitive en-hancement and treatment of neurodegenerative diseases. Our analysis provides insights into the mechanism of action of HDAC inhibitors, associated epigenetic priming, and describes the thera-peutic success and potential complications after unsupervised use of the inhibitors. Results and Conclusion: Several chromatin-modifying enzymes play key roles in the regulation of cognitive processes. The importance of HDAC signaling in the brain is highlighted in this review. Recent advancements in the field of cognitive epigenetics are supported by the successful develop-ment of various HDAC inhibitors, demonstrating effective treatment of mood-associated disorders. The current review discusses the therapeutic potential of HDAC inhibition and observed complica-tions after mood and cognitive enhancement therapies.
- 3 December 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (12) , 6609-6618
Identification of CpG Sites of SERPINA5 Promoter with Opposite Methylation Patterns in Benign and Malignant Prostate Cells
Background/Aim: To date there has been no investigation into the epigenetic regulation of the serine protease inhibitor SERPINA5 in prostate cancer, where lack of this gene was considered to facilitate invasive growth patterns. Materials and Methods: Methylation degrees of eight CpG sites of SERPINA5 were analyzed in normal and malignant prostate cells using nucleotide sequencing, methylation-specific high resolution melting and digital droplet PCR techniques. Results: The methylation degree of five CpG sites significantly correlated with lower SERPINA5 expression levels. In contrast, two CpG sites (at -19 bp and -14 bp from the transcription start site) were hypermethylated in normal epithelial prostate cells, benign hyperplasic cells and low-invasive malignant LNCaP cells, whereas in aggressive DU-145 and PC-3 cell lines, these sites were essentially unmethylated. Conclusion: Novel methylation patterns of two distinct CpG sites of the SERPINA5 promoter may be useful for differentiating benign from malignant prostate disease.
- 3 December 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (12) , 6609-6618
Identification of CpG Sites of SERPINA5 Promoter with Opposite Methylation Patterns in Benign and Malignant Prostate Cells
Background/Aim: To date there has been no investigation into the epigenetic regulation of the serine protease inhibitor SERPINA5 in prostate cancer, where lack of this gene was considered to facilitate invasive growth patterns. Materials and Methods: Methylation degrees of eight CpG sites of SERPINA5 were analyzed in normal and malignant prostate cells using nucleotide sequencing, methylation-specific high resolution melting and digital droplet PCR techniques. Results: The methylation degree of five CpG sites significantly correlated with lower SERPINA5 expression levels. In contrast, two CpG sites (at -19 bp and -14 bp from the transcription start site) were hypermethylated in normal epithelial prostate cells, benign hyperplasic cells and low-invasive malignant LNCaP cells, whereas in aggressive DU-145 and PC-3 cell lines, these sites were essentially unmethylated. Conclusion: Novel methylation patterns of two distinct CpG sites of the SERPINA5 promoter may be useful for differentiating benign from malignant prostate disease.
- 1 April 2014
- Vol. 34 (4) , 1723-9
Silibinin down-regulates expression of secreted phospholipase A2 enzymes in cancer cells.
Silibinin, a naturally-occurring flavonoid produced by milk thistle, possesses antioxidant, anti-inflammatory and cancer-preventive activities. In the current study, we examined the effects of silibinin on the expression of secreted phospholipase A2 (sPLA2) enzymes, especially those of group IIA (hGIIA), which play a crucial role in inflammation and carcinogenesis. The effects of silibinin on sPLA2 expressions in human HepG2 hepatoma and PC-3 prostate cancer cells were analyzed using quantitative reverse transcription-polymerase chain reaction and enzyme linked immunosorbent assay technique. Silibinin inhibited the expression of hGIIA in unstimulated and cytokine-primed HepG2 and PC-3 cells. The mRNA levels of sPLA2 of groups IB, III and V were also significantly decreased by silibinin. Analyses of transcription factor activation suggest that nuclear factor-κB, but not specificity protein 1 (SP1) is implicated in the silibinin-mediated down-regulation of hGIIA. Silibinin exhibits inhibitory effects on basal and cytokine-induced expression of sPLA2s in cancer cells and therefore, may have the potential to protect against up-regulation of hGIIA and other sPLA2 isoforms during inflammation and cancer.
- 1 April 2014
- Vol. 34 (4) , 1723-9
Silibinin down-regulates expression of secreted phospholipase A2 enzymes in cancer cells.
Silibinin, a naturally-occurring flavonoid produced by milk thistle, possesses antioxidant, anti-inflammatory and cancer-preventive activities. In the current study, we examined the effects of silibinin on the expression of secreted phospholipase A2 (sPLA2) enzymes, especially those of group IIA (hGIIA), which play a crucial role in inflammation and carcinogenesis. The effects of silibinin on sPLA2 expressions in human HepG2 hepatoma and PC-3 prostate cancer cells were analyzed using quantitative reverse transcription-polymerase chain reaction and enzyme linked immunosorbent assay technique. Silibinin inhibited the expression of hGIIA in unstimulated and cytokine-primed HepG2 and PC-3 cells. The mRNA levels of sPLA2 of groups IB, III and V were also significantly decreased by silibinin. Analyses of transcription factor activation suggest that nuclear factor-κB, but not specificity protein 1 (SP1) is implicated in the silibinin-mediated down-regulation of hGIIA. Silibinin exhibits inhibitory effects on basal and cytokine-induced expression of sPLA2s in cancer cells and therefore, may have the potential to protect against up-regulation of hGIIA and other sPLA2 isoforms during inflammation and cancer.
- 1 June 2013
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 94 (3) , 458-465
Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: Role of epigenetic mechanisms
- 1 June 2013
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 94 (3) , 458-465
Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: Role of epigenetic mechanisms
- Open Access
- 5 December 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 576
Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells
The M-type phospholipase A2 receptor (PLA2R1) plays a crucial role in several signaling pathways and may act as tumor-suppressor. This study examined the expression and methylation of the PLA2R1 gene in Jurkat and U937 leukemic cell lines and its methylation in patients with myelodysplastic syndrome (MDS) or acute leukemia.
- 5 December 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 576
Open AccessAberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells
The M-type phospholipase A2 receptor (PLA2R1) plays a crucial role in several signaling pathways and may act as tumor-suppressor. This study examined the expression and methylation of the PLA2R1 gene in Jurkat and U937 leukemic cell lines and its methylation in patients with myelodysplastic syndrome (MDS) or acute leukemia.
- Open Access
- 1 January 2011
- Published by Springer Nature in Cancer Cell International
- Vol. 11 (1) , 4
Expression and shedding of endothelial protein C receptor in prostate cancer cells
Increasing evidences show that beyond its role in coagulation, endothelial protein C receptor (EPCR) interferes with carcinogenesis. Pro-carcinogenic effects of EPCR were linked with a raised generation of activated protein C (aPC) and anti-apoptotic signalling. This study was carried out to analyze the expression, cell surface exposition, and shedding of EPCR in normal and malignant prostate cell lines.
- 1 January 2011
- Published by Springer Nature in Cancer Cell International
- Vol. 11 (1) , 4
Open AccessExpression and shedding of endothelial protein C receptor in prostate cancer cells
Increasing evidences show that beyond its role in coagulation, endothelial protein C receptor (EPCR) interferes with carcinogenesis. Pro-carcinogenic effects of EPCR were linked with a raised generation of activated protein C (aPC) and anti-apoptotic signalling. This study was carried out to analyze the expression, cell surface exposition, and shedding of EPCR in normal and malignant prostate cell lines.
- 1 May 2001
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1512 (1) , 98-110
Influence of plant terpenoids on the permeability of mitochondria and lipid bilayers
- 1 May 2001
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1512 (1) , 98-110
Influence of plant terpenoids on the permeability of mitochondria and lipid bilayers
- 1 October 1997
- Published by Elsevier in Cell Calcium
- Vol. 22 (4) , 235-241
Ionophoretic properties of ferutinin
- 1 October 1997
- Published by Elsevier in Cell Calcium
- Vol. 22 (4) , 235-241
Ionophoretic properties of ferutinin